Allogene Therapeutics (ALLO) reports interim Phase 2 trial results

AI Summary

Allogene Therapeutics (ALLO) announced interim results from its Phase 2 ALPHA3 trial for cema-cel in lymphoma. The trial aimed to evaluate the efficacy and safety of the therapy. Key findings from the trial include specific responses in patient outcomes, though numbers were not disclosed in the announcement. The results could influence market sentiment regarding ALLO's future performance and the potential for cema-cel as a treatment option in oncology.